Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECEDENT: SAGE-718 in Parkinson's Disease Cognitive Impairment
NCT05318937Phase 2Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Jun 2022
- Primary completion
- Jan 2024
- Modality
- Allosteric Modulators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of dalzanemdor in Mild Cognitive Impairment in Parkinson’s Disease (PD-MCI), sponsored by Supernus Pharmaceuticals, Inc.. Started Jun 2022; status: completed.
02
Drugs
dalzanemdor
03
Conditions
Mild Cognitive Impairment in Parkinson’s Disease (PD-MCI)
Beyond the preview
Go deeper on NCT05318937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05318937.